First patient enrollment in MASCOT registry represents major milestone for COMBO™ Dual Therapy Stent.
2,500-patient, 50-center study is the largest post-marketing registry on the safety and effectiveness of the COMBO Stent.
HONG KONG, July 16, 2014 – OrbusNeich today announced that the first patient has been enrolled in the Multinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) post-marketing registry.
Latest results further support excellent healing benefits of World’s first and only Dual Therapy Stent .
Genoa, Italy, 17th October, 2014 - Latest data presented on the COMBO Dual Therapy Stent, provides further evidence to support the long-term safety and efficacy of the stent in the treatment of coronary artery disease.